Skip to main content
Premium Trial:

Request an Annual Quote

Cell-based Dx Firm Lophius Biosciences Raises $5.3M

NEW YORK (GenomeWeb News) – T-cell-based diagnostics development firm Lophius Biosciences today announced the closing of a financing round that brought in €4 million ($5.3 million) in funding.

Lophius will use the cash infusion to launch its technologies, it said. VRD and WIC were new investors in the round. Existing investors include S-Refit, HighTech Gründerfonds, Bayern Kapital and two angel investors.

The Regensburg, Germany-based company also announced Ralf Wagner has been named managing director. He will focus on rounding out and launching Lophius' product portfolio. Wagner was founder, CEO, and CSO of GeneArt, which was acquired by Life Technologies in 2010.

Lophius develops T-cell based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases. In 2011, it raised $2 million in a private financing.